Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 47.95
Bid: 47.60
Ask: 47.95
Change: -1.10 (-2.24%)
Spread: 0.35 (0.735%)
Open: 49.40
High: 49.45
Low: 47.75
Prev. Close: 49.05
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pre-closed-period update

13 Jan 2022 07:00

RNS Number : 2824Y
IP Group PLC
13 January 2022
 

FOR RELEASE ON

13 January 2022

 

IP Group plc - pre-closed-period update

 

Highlights

· FY21 profit anticipated to be above £425m (FY20: profit £185.4m)

· FY21 Hard NAV per share* anticipated to be above 165p (FY20: 125.3p), a return of at least 31%

· Net cash and deposits of £276m at 31 Dec 2021 (FY20: £203m)

· Portfolio companies well-funded having raised over £2bn in 2021 (FY20: £1.1bn)

 

IP Group plc (LSE: IPO) ("IP Group", "the Company" or "the Group"), the developer of intellectual property-based businesses, issues an unaudited pre-close update ahead of its results for the 12 months to 31 December 2021.

 

In financial terms, 2021 was another highly successful year with a large number of significant transactions including the flotation of Oxford Nanopore Technologies plc on the London Stock Exchange and the sales of Inivata Ltd and WaveOptics Ltd.

 

Consequently, the Directors currently expect the Group's profit for 2021 to be above £425m (FY20: profit £185.4m). Hard NAV per share is anticipated to be above 165 pence, a return of at least 31%.

 

The Group is in a strong financial position with net cash and deposits of £276m at year-end. The Group's portfolio is well funded with portfolio companies having raised over £2bn in 2021 (FY20: £1.1bn). This, combined with the exciting prospects and investment opportunities within the portfolio, gives us confidence for 2022.

 

IP Group expects to announce its 2021 results in mid-March.

 

Notes

 

*'Hard NAV per share' reflects net assets/total equity less goodwill and intangibles divided by outstanding shares.

 

The share price of Oxford Nanopore Technologies plc was 697 pence at 31 December 2021.

 

This update is based on unaudited information and is subject to change following the completion of the Group's usual full year-end reporting process and annual audit.

 

This announcement may contain forward looking statements. These statements reflect the Board's current view, are subject to a number of material risks and uncertainties and could change in the future. Factors which could cause or contribute to such changes include, but are not limited to, the general economic climate and market conditions, as well as specific factors relating to the financial or commercial prospects or performance of individual companies within the Group's portfolio.

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

David Baynes, Chief Financial and Operating OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDBGDBCSBDGDD
Date   Source Headline
29th Oct 20212:02 pmRNSPortfolio co Hinge Health completes $400m round
28th Oct 20216:21 pmRNSTransaction in Own Shares
27th Oct 20215:43 pmRNSDirector/PDMR Shareholding
27th Oct 20215:25 pmRNSTransaction in Own Shares
26th Oct 20215:56 pmRNSTransaction in Own Shares
25th Oct 20216:28 pmRNSTransaction in Own Shares
25th Oct 20217:00 amRNSAdditional fair value gain of £27.5m
22nd Oct 20216:29 pmRNSTransaction in Own Shares
21st Oct 20216:00 pmRNSTransaction in Own Shares
20th Oct 20215:56 pmRNSTransaction in Own Shares
19th Oct 20216:31 pmRNSTransaction in Own Shares
19th Oct 20217:00 amRNSTransaction in Own Shares
18th Oct 20217:00 amRNSTransaction in Own Shares
14th Oct 20216:27 pmRNSTransaction in Own Shares
13th Oct 20216:22 pmRNSTransaction in Own Shares
13th Oct 202111:36 amRNSDirector Declaration
13th Oct 20219:03 amRNSHolding(s) in Company
12th Oct 20216:20 pmRNSTransaction in Own Shares
12th Oct 20212:09 pmRNSDirector/PDMR Shareholding
12th Oct 20217:00 amRNSTransaction in Own Shares
11th Oct 20217:41 amRNSTransaction in Own Shares
8th Oct 20217:00 amRNSShare buyback programme
6th Oct 20217:00 amRNSBoard changes
5th Oct 20214:44 pmRNSHolding(s) in Company
30th Sep 20214:11 pmRNSTotal Voting Rights
30th Sep 20217:45 amRNSIP Group generates £84m from Oxford Nanopore IPO
27th Sep 202112:40 pmRNSDirector/PDMR Shareholding
23rd Sep 20213:57 pmRNSFurther re Scrip Dividend
16th Sep 20217:08 amRNSOxford Nanopore confirms ITF; MoU with Oracle
10th Sep 20215:21 pmRNSHolding(s) in Company
8th Sep 202110:53 amRNSDirector/PDMR Shareholding, SAYE scheme
19th Aug 202110:41 amRNSScrip Dividend Reference Price
12th Aug 20215:05 pmRNSDirector Declaration
5th Aug 20217:00 amRNSHalf-yearly results
27th Jul 20217:03 amRNSPortfolio company Artios Pharma raises $153m
22nd Jul 202111:30 amRNSNotice of Results
1st Jul 20217:00 amRNSTotal Voting Rights
28th Jun 20217:30 amRNSDirector/PDMR Shareholding
18th Jun 20219:52 amRNSDirector/PDMR Shareholding
17th Jun 20217:00 amRNSPortfolio company Apollo Therapeutics raises $145m
15th Jun 20218:00 amRNSFurther re Scrip Dividend
9th Jun 202111:29 amRNSResult of AGM
9th Jun 20217:00 amRNSAGM Statement
7th Jun 20217:00 amRNSPortfolio co Iksuda completes $42m financing round
28th May 20213:36 pmRNSDirector/PDMR Shareholding
28th May 202110:00 amRNSJoint venture with China Everbright to launch fund
27th May 20217:00 amRNSPortfolio co Pulmocide completes $92m Series C
26th May 20212:44 pmRNSUpdate on AGM
20th May 202110:01 amRNSScrip Dividend Reference Price
17th May 202112:44 pmRNSAdditional fair value gain of £20m

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.